PPT-Presentation at the 20th International Myeloma

Presentation at the 20th International Myeloma Society Annual Meeting September 2730 2023 Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma IKEMA Overall. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . Miss Georgia Stewart . Sheffield Myeloma Research Team. Department of Oncology and Metabolism. Faculty of Medicine Dentistry and Health . University of Sheffield, UK. Most Viruses have a preferential tropism for tumour cells. Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT. [Hospital]. [date]. Myeloma: Symptoms to diagnosis . Can we do better?.